About this Research Topic
Immunotherapy has emerged as a promising therapeutic avenue due to the radical increase in the failure rate of conventional treatment (surgery, chemo/radio) paradigms. Despite understanding the significance of immunogenic therapeutic mechanisms and their vast potential to enhance cytotoxic therapeutic responses, immunotherapy has thus far achieved only marginal success, posing challenges for its translation into clinical practice. This can be attributed to the limited availability of neoantigens and the inability to deliver such antigens in a manner that renders them immunogenic in cancer patients. This is complicated by the tumor immune microenvironment (TIME), which provides a daunting barrier to immune
infiltration and normal cellular function. Recently, neoantigen-targeted immunotherapy has emerged as a rapidly advancing field, offering significant promise in cancer treatment. In tumor-specific killing, recognition of tumor-specific neoantigens with high immunogenicity generated by mutations in cancer cells is a crucial step. Such specificity renders neoantigens highly attractive as therapeutic targets in the fight against cancer.
The development of cancer therapies will be aided by understanding the mechanisms underlying neoantigen-induced anti-tumor immune responses and by streamlining the process of neoantigen-based immunotherapies. Even though several extensive studies have gained insights into the relationship between immunotherapy response and TIME, the mechanisms of how cancer cells modulate the immune composition of TIME still remain unclear. Also, precise immunotherapy responses are still difficult to attain due to a lack of effective predictive
biomarkers and neoantigens.
Understanding the interplay between the TIME and neoantigens is essential for the development of more effective cancer immunotherapies. By targeting both components, researchers can potentially overcome the challenges of immune evasion and resistance, leading to improved treatment outcomes for cancer patients. As the field of cancer immunotherapy continues to evolve, the integration of TIME and neoantigen research will be crucial for the advancement of personalized and effective cancer therapies. Hence, it is vital to investigate the deeper understanding of such crosstalk for effective immunotherapeutic regimes.
Topics of interest include, but are not limited to:
• How is neoantigen generation influenced by the TIME? What is the role of immune
cells, cytokines, and other factors in neoantigen presentation?
• How does the TIME contribute to immunosuppression and immune escape? What
are the mechanisms by which neoantigens can overcome these barriers?
• How does the TIME regulate immune cell infiltration and activation? What are the
factors that promote or inhibit the antitumor immune response?
• What are the current and emerging approaches for targeting neoantigens in
immunotherapy including cancer vaccines, adoptive cell therapy, antibody-based
therapy etc?
• Improved computational methods to predict potential neoantigens
We welcome submissions in the following formats: Original Research Articles,
Reviews, Perspectives, Case Reports, Mini-reviews, and Observations.
infiltration and normal cellular function. Recently, neoantigen-targeted immunotherapy has emerged as a rapidly advancing field, offering significant promise in cancer treatment. In tumor-specific killing, recognition of tumor-specific neoantigens with high immunogenicity generated by mutations in cancer cells is a crucial step. Such specificity renders neoantigens highly attractive as therapeutic targets in the fight against cancer.
The development of cancer therapies will be aided by understanding the mechanisms underlying neoantigen-induced anti-tumor immune responses and by streamlining the process of neoantigen-based immunotherapies. Even though several extensive studies have gained insights into the relationship between immunotherapy response and TIME, the mechanisms of how cancer cells modulate the immune composition of TIME still remain unclear. Also, precise immunotherapy responses are still difficult to attain due to a lack of effective predictive
biomarkers and neoantigens.
Understanding the interplay between the TIME and neoantigens is essential for the development of more effective cancer immunotherapies. By targeting both components, researchers can potentially overcome the challenges of immune evasion and resistance, leading to improved treatment outcomes for cancer patients. As the field of cancer immunotherapy continues to evolve, the integration of TIME and neoantigen research will be crucial for the advancement of personalized and effective cancer therapies. Hence, it is vital to investigate the deeper understanding of such crosstalk for effective immunotherapeutic regimes.
Topics of interest include, but are not limited to:
• How is neoantigen generation influenced by the TIME? What is the role of immune
cells, cytokines, and other factors in neoantigen presentation?
• How does the TIME contribute to immunosuppression and immune escape? What
are the mechanisms by which neoantigens can overcome these barriers?
• How does the TIME regulate immune cell infiltration and activation? What are the
factors that promote or inhibit the antitumor immune response?
• What are the current and emerging approaches for targeting neoantigens in
immunotherapy including cancer vaccines, adoptive cell therapy, antibody-based
therapy etc?
• Improved computational methods to predict potential neoantigens
We welcome submissions in the following formats: Original Research Articles,
Reviews, Perspectives, Case Reports, Mini-reviews, and Observations.
Keywords: Tumor immune microenvironment, Neoantigens, Immune cells, Immunotherapy, Therapeutic targets
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.
